{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:10:19Z","timestamp":1791414619418,"version":"4.3.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,12,13]],"date-time":"2006-12-13T00:00:00Z","timestamp":1165968000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2007,7,17]]},"DOI":"10.1007\/s00280-006-0392-5","type":"journal-article","created":{"date-parts":[[2006,12,12]],"date-time":"2006-12-12T08:21:28Z","timestamp":1165911688000},"page":"503-507","source":"Crossref","is-referenced-by-count":53,"title":["DPYD*2A mutation: the most common mutation associated with DPD deficiency"],"prefix":"10.1007","volume":"60","author":[{"given":"M. W.","family":"Saif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany","family":"Ezzeldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katisha","family":"Vance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sellers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Diasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,12,13]]},"reference":[{"key":"392_CR1","first-page":"432","volume-title":"Cancer: principles and practice of oncology,","author":"CJ Allegra","year":"1997","unstructured":"Allegra CJ, Grem JL (1997) Antimetabolites. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 5th edn. Lippincott-Raven, Philadelphia, pp 432\u2013451","edition":"5"},{"key":"392_CR2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1200\/JCO.1997.15.1.368","volume":"15","author":"AF Sobrero","year":"1997","unstructured":"Sobrero AF, Aschele C, Bertino JR (1997) Fluorouracil in colorectal cancer: a tale of two drugs\u2014implications for biochemical modulation. J Clin Oncol 15:368\u2013381","journal-title":"J Clin Oncol"},{"key":"392_CR3","first-page":"149","volume-title":"Cancer chemotherapy and biotherapy: principles and practice","author":"JL Grem","year":"1996","unstructured":"Grem JL (1996) 5-Fluoropyrimidines In: Chabner BA, Longo DL (eds) Cancer chemotherapy and biotherapy: principles and practice. Lippincott-Raven, Philadelphia, pp 149\u2013211"},{"key":"392_CR4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3816\/CCC.2004.n.018","volume":"4","author":"H Ezzeldin","year":"2004","unstructured":"Ezzeldin H, Diasio R (2004) Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer 4:181\u2013189","journal-title":"Clin Colorectal Cancer"},{"key":"392_CR5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0065-2571(00)00011-X","volume":"41","author":"MR Johnson","year":"2001","unstructured":"Johnson MR, Diasio R (2001) Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul 41:151\u2013157","journal-title":"Adv Enzyme Regul"},{"key":"392_CR6","first-page":"4705","volume":"12","author":"AB Kuilenburg Van","year":"2000","unstructured":"Van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, DeAbreu RA, Maring JG, Vreken P, Van Gennip AH (2000) Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity; identification of new mutations in the DPD gene. Clin Cancer Res 12:4705\u20134012","journal-title":"Clin Cancer Res"},{"issue":"3","key":"392_CR7","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s00280-005-0174-5","volume":"58","author":"MW Saif","year":"2006","unstructured":"Saif MW, Mattison L, Carollo T, Ezzeldin H, Diasio RB (2006) Dihydropyrimidine dehydrogenase deficiency in an Indian population. Cancer Chemother Pharmacol 58(3):396\u2013401","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"392_CR8","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3816\/CCC.2006.n.007","volume":"5","author":"MW Saif","year":"2006","unstructured":"Saif MW, Diasio R (2006) Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency? Clin Colorectal Cancer 5(5):359\u2013362","journal-title":"Clin Colorectal Cancer"},{"key":"392_CR9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/abio.2002.5666","volume":"306","author":"H Ezzeldin","year":"2002","unstructured":"Ezzeldin H, Okamoto Y, Johnson MR, Diasio RB (2002) A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency. Anal Biochem 306:63\u201373","journal-title":"Anal Biochem"},{"key":"392_CR10","first-page":"3021","volume":"9","author":"H Ezzeldin","year":"2003","unstructured":"Ezzeldin H, Johnson MR, Okamoto Y, Diasio RB (2003) Denaturing high performance liquid chromatography (DHPLC) analysis of the DPYD gene in patients with lethal 5-fluorouracil (5-FU) toxicity. Clin Cancer Res 9:3021\u20133028","journal-title":"Clin Cancer Res"},{"issue":"9","key":"392_CR11","first-page":"2832","volume":"7","author":"M Raida","year":"2001","unstructured":"Raida M et al (2001) Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5\u2032-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 7(9): 2832\u20132839","journal-title":"Clin Cancer Res"},{"key":"392_CR12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0378-4347(97)00253-3","volume":"696","author":"MR Johnson","year":"1997","unstructured":"Johnson MR, Yan J, Shao L, Albin N, Diasio RB (1997) Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatogr B Biomed Sci Appl 696:183\u2013191","journal-title":"J Chromatogr B Biomed Sci Appl"},{"issue":"8","key":"392_CR13","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1158\/1078-0432.CCR-03-0374","volume":"10","author":"LK Mattison","year":"2004","unstructured":"Mattison LK, Ezzeldin H, Carpenter M, Modak A, Johnson MR, Diasio RB (2004) Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin Cancer Res 10(8):2652\u20132658","journal-title":"Clin Cancer Res"},{"key":"392_CR14","first-page":"3964","volume":"42","author":"DS Martin","year":"1982","unstructured":"Martin DS, Stolfi RL, Sawyer RC et al (1982) High-dose 5 fluorouracil with delayed \u201curidine\u201d rescue in mice. Res 42:3964\u20133970","journal-title":"Res"},{"key":"392_CR15","first-page":"1","volume":"27","author":"MW Saif","year":"2005","unstructured":"Saif MW, von Borstel R (2005) 5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice. Cancer Chemother Pharmacol 27:1\u20137","journal-title":"Cancer Chemother Pharmacol"},{"key":"392_CR16","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1200\/JCO.1997.15.4.1511","volume":"15","author":"DP Kelsen","year":"1997","unstructured":"Kelsen DP, Martin D, O\u2019Neil J et al (1997) Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. J Clin Oncol 15:1511\u20131517","journal-title":"J Clin Oncol"},{"issue":"1","key":"392_CR17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1200\/JCO.2000.18.1.167","volume":"18","author":"M Hidalgo","year":"2000","unstructured":"Hidalgo M, Villalona-Calero MA, Eckhardt SG, Drengler RL, Rodriguez G, Hammond LA, Diab SG, Weiss G, Garner AM, Campbell E, Davidson K, Louie A, O\u2019Neil JD, von Borstel R, Von Hoff DD, Rowinsky EK (2000) Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. J Clin Oncol 18(1):167\u2013177","journal-title":"J Clin Oncol"},{"key":"392_CR18","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0006-2952(00)00342-7","volume":"60","author":"OM Ashour","year":"2000","unstructured":"Ashour OM, Naguib FN, Panzica RP, Al Safarjalani ON, el Kouni MH (2000) Modulation of 5-fluorouracil host toxicity by 5-(benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2\u2032,3\u2032,5\u2032-tri-O-acetyluridine, a prodrug of uridine. Biochem Pharmacol 60:427\u2013431","journal-title":"Biochem Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-006-0392-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-006-0392-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-006-0392-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T06:06:26Z","timestamp":1559023586000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-006-0392-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12,13]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,7,17]]}},"alternative-id":["392"],"URL":"https:\/\/doi.org\/10.1007\/s00280-006-0392-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12,13]]}}}